A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX

Oncologist. 2024 Feb 23:oyad315. doi: 10.1093/oncolo/oyad315. Online ahead of print.ABSTRACTHomologous recombination repair (HRR) pathway deficiency opens multiple therapeutic avenues within pancreatic cancer. Patients with HRR deficiency-associated gene mutations such as BRCA1, BRCA2, and PALB2 are more susceptible to platinum-based chemotherapies and in those with somatic BRCA mutations, PARP inhibitor therapy prolongs progression-free survival. The case discussed herein illustrates the therapeutic opportunities offered through the identification of HRR deficiency in pancreatic cancer, as well as the challenges associated with treatment and prevention of central nervous system metastases in long-term survivors of pancreatic cancer.PMID:38394390 | DOI:10.1093/oncolo/oyad315

Source: The Oncologist - February 23, 2024 Category: Cancer & Oncology Authors: Jacob K Jamison Michael S May Alexander G Raufi Lyndon Luk Winston Wong Prabhjot S Mundi Gulam A Manji Source Type: research